New combo therapy aims to boost liver cancer survival
NCT ID NCT06999694
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new combination treatment for people with advanced liver cancer that cannot be removed by surgery. It combines precise proton radiation with two immunotherapy drugs, tremelimumab and durvalumab. The goal is to see if this approach is safe and works better than current treatments. About 45 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Proton radiotherapy, tremelimumab, and durvalumab
What this could lead to
If successful, this combination could offer a more effective treatment option for advanced liver cancer, potentially improving survival and tumor control.
What could go wrong
This is an early phase 2 trial with only 45 participants, so results may not apply to everyone. Side effects from the drugs and radiation can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Memorial Hospital at Linkou
RECRUITINGTaoyuan City, Taiwan, 333, Taiwan
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••